Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (4583)	10/19/2000 1:50:35 PM
From: rkrw	Respond to of 10280

Scott, If there were any improper trading, I'd think the window for knowledge of this was probably quite narrow. On the CC, Sepracor claimed LLY informed them of their decision last night. So advance knowledge would have to have come from between the time when LLY informed Sepr of the QT issue and last nights decision to return the drug, if in fact, LLY forewarned them at all. LLY was publicly trumpeting the drug in mid August in the aftermath of the patent overturn. I think Sepracor has handled the situation reasonably. They were blunt regarding the financial and strategic implications of the LLY decision.